New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

LB Pharmaceuticals Inc (LBRX) vs Ocular Therapeutix, Inc. (OCUL)

LB Pharmaceuticals Inc and Ocular Therapeutix, Inc. are both Biotechnology companies. LB Pharmaceuticals Inc and Ocular Therapeutix, Inc. are of similar size ($1.3B and $1.3B). LB Pharmaceuticals Inc has the higher net margin (0.00% vs −648.6%) and the lower return on invested capital (−686.2% vs 0.00%). Across the 13 metrics below, LB Pharmaceuticals Inc leads on 10 and Ocular Therapeutix, Inc. on 3.

Valuation

Metric LBRX OCUL Biotechnology median
P/E n/m n/m 8.26
P/S n/m 26.23 9.20
P/B 3.17 3.00 2.09
Price to free cash flow n/m n/m 24.49
EV/EBITDA n/m n/m 0.67
EV/Sales n/m 17.16 9.05
Earnings yield (11.54%) (24.92%) (34.24%)
Free cash flow yield (10.86%) (20.21%) (24.77%)

Profitability

Metric LBRX OCUL Biotechnology median
Gross margin — 87.32% 70.18%
Operating margin 0.00% (680.91%) 0.00%
Net margin 0.00% (648.64%) 0.00%
Free cash flow margin 0.00% (530.00%) 0.00%
Return on equity (38.80%) (93.48%) (51.58%)
Return on assets (36.48%) (64.30%) (45.91%)
Return on invested capital (686.18%) 0.00% 0.00%

Growth

Metric LBRX OCUL Biotechnology median
Revenue growth (TTM) — (9.68%) 7.20%
EPS growth (last fiscal year) 98.22% (16.39%) 29.04%
Revenue growth, 5-year CAGR — 24.45% 9.48%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric LBRX OCUL Biotechnology median
Debt to equity 0.00 0.17 0.00
Current ratio 14.78 9.12 4.83
Net debt to EBITDA 9.90 2.51 1.01

Dividend

Metric LBRX OCUL Biotechnology median
Dividend yield — — 0.40%
Payout ratio — — —

Size

Metric LBRX OCUL Biotechnology median
Market cap 1.30b 1.29b 155.23m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack